Promise and Peril of Pretomanid–Rifamycin Regimens for Drug-susceptible Tuberculosis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Promise and Peril of Pretomanid–Rifamycin Regimens for Drug-susceptible Tuberculosis

Published:2023-04-01 Issue:7 Volume:207 Page:816-818
ISSN:1073-449X
Container-title:American Journal of Respiratory and Critical Care Medicine
language:en
Short-container-title:Am J Respir Crit Care Med

Author:

Velásquez Gustavo E.¹²^ORCID,Nahid Payam¹³^ORCID

Affiliation:

1. UCSF Center for Tuberculosis

2. Division of HIV, Infectious Diseases, and Global MedicineUniversity of California San FranciscoSan Francisco, California

3. Division of Pulmonary and Critical Care MedicineUniversity of California San FranciscoSan Francisco, California

Publisher

American Thoracic Society

Subject

Critical Care and Intensive Care Medicine,Pulmonary and Respiratory Medicine

Link

https://www.atsjournals.org/doi/pdf/10.1164/rccm.202212-2262ED

Reference13 articles.

1. Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis

2. Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis — United States, 2022

3. Novel Regimens of Bedaquiline-Pyrazinamide Combined with Moxifloxacin, Rifabutin, Delamanid and/or OPC-167832 in Murine Tuberculosis Models

4. Enhanced Bactericidal Activity of Rifampin and/or Pyrazinamide When Combined with PA-824 in a Murine Model of Tuberculosis

5. Early Bactericidal Activity and Pharmacokinetics of PA-824 in Smear-Positive Tuberculosis Patients

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP